Sigma non-opioid intracellular receptor 1
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sigma non-opioid intracellular receptor 1 as ChEMBL target CHEMBL4153, mapped to UniProt Q60492. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Sigma non-opioid intracellular receptor 1 matters
Sigma non-opioid intracellular receptor 1 is reviewed as Sigma non-opioid intracellular receptor 1 (UniProt Q60492); the current evidence base includes 13 approved drugs, 3019 compounds, and 308 assays, with lead potency reaching pChEMBL 11.0.
Sigma non-opioid intracellular receptor 1 Sequence length is 223 aa.
Review this target as Sigma non-opioid intracellular receptor 1, mapped to UniProt Q60492. Sequence length is 223 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 13 approved drugs, 3019 compounds, and 308 assays for this target. The dominant activity type is KI. CHEMBL372700 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL372700 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Sigma non-opioid intracellular receptor 1 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q60492, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL372700
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL545278
|
10.5 | Ki | — |
|
|
No preferred name
CHEMBL176941
|
10.5 | Ki | — |
|
|
No preferred name
CHEMBL76758
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL1917286
|
10.3 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
PITOLISANT
CHEMBL462605
|
2016 |
|
|
DOLUTEGRAVIR
CHEMBL1229211
|
2013 |
|
|
DONEPEZIL
CHEMBL502
|
1996 |
|
|
DEXTROMETHORPHAN
CHEMBL52440
|
1982 |
|
|
PROGESTERONE
CHEMBL103
|
1976 |
|
|
HALOPERIDOL
CHEMBL54
|
1967 |
|
|
PENTAZOCINE
CHEMBL100116
|
1967 |